# US 2024/0391871 A1 · Substituted hydroxymethyl pyrrolidines and medical uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391871 A1
- Document ID: US20240391871A1
- Status: Published application
- Kind: A1
- Application number: 18/693,573
- Filed: 2022-09-23
- Published: 2024-11-28
- Earliest claimed: 2021-09-23
- Assignees: Atrogi AB
- Applicants: Atrogi AB
- Inventors: Tore Bengtsson; Benjamin Pelcman
- Web page: https://patentgrep.com/patent/US20240391871A1

## CPC

- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1, ring A and the ring containing Q1 to Q5 have meanings as provided in the description. There is also provided medical uses of such compounds.

## Claims

### Claim 1

A compound of formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1 represents H or C1-6 alkyl;
the ring comprising Q1 to Q5 represents:
a phenyl optionally substituted with one or more Y1, or
a 5- or 6-membered heteroaryl optionally substituted with one or more Y2;
the ring comprising A represents:
a 4- to 8-membered saturated or partially saturated carbocycle, optionally substituted by one or more Z1; or
phenyl optionally substituted by one or more Z2;
each Y1 independently represents halo, Ra1, —CN or —N3;
each Y2 independently represent halo, Ra2, —CN or —N3;
each Z1 independently represents halo, Ra3, —CN, —N3, —N(Rb3)Rc3, —ORd3, —S(O)pRe3, —S(O)qN(Rf3)Rg3 or —N(Rh3)S(O)tRi3;
each Z2 independently represents halo, Ra4, —CN, —N3, —N(Rb4)Rc4, —ORd4, —S(O)pRe4, —S(O)qN(Rf4)Rg4 or —N(Rh4)S(O)t(Ri4;
each Ra1 and Ra2 independently represents C1-6 alkyl optionally substituted by one or more halo;
each Ra3, Ra4 Re3, Re4, Ri3 and Ri4 independently represents C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl each optionally substituted by one or more groups independently selected from halo and G1;
each Rb3, Rb4, Rc3, Rc4, Rd3, Rd4, Rf3, Rf4 Rg3, Rg4, Rh3 and Rh4 independently represents H,
C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl each optionally substituted by one or more groups independently selected from halo and G2;
or alternatively any of Rb3 and Rc3, Rf3 and Rg3, Rb4 and Rc4, and/or Rf4 and Rg4 may be linked together to form, together with the nitrogen atom to which they are attached, a 4- to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from halo, C1-3 alkyl optionally substituted by one or more halo, and ═O;
each G1 and G2 independently represents Ra5, —CN, —N3, —N(Rb5)Rc5, —ORd5, —S(O)pRe5, —S(O)qN(Rf5)Rg5, or ═O;
each Ra5 independently represents phenyl or 5- or 6-membered heteroaryl, each optionally substituted by one or more group selected from halo, —CN or C1-3 alkyl optionally substituted by one or more halo or —CN;
each Rb5, Rc5, Rd5, Rf5 and Rg5 independently represents H, or C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl optionally substituted by one or more halo or —CN;
each Re5 independently represents C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl each optionally substituted by one or more halo or —CN;
or alternatively any of Rb5 and Rc5 and/or Rf5 and Rg5 may be linked together to form, together with the nitrogen atom to which they are attached, a 4- to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from halo, C1-3 alkyl optionally substituted by one or more halo, and ═O;
each p independently represents 0, 1 or 2;
each q independently represents 1 or 2; and
each t independently represents 1 or 2.

### Claim 2 (depends on 1)

The compound according to claim 1, the ring comprising Q1 to Q5 represents:
phenyl optionally substituted with one or more Y1; or
pyridyl optionally substituted with one or more Y2.

### Claim 3

The compound according to any one of the preceding claims, wherein each Y1 independently represents Ra1, halo or —CN.

### Claim 4

The compound according to any one of the preceding claims, each Y2 independently represents Ra2, halo or —CN.

### Claim 5

The compound according to any one of the preceding claims, wherein each Y1 and Y2 represents Cl or F.

### Claim 6

The compound according to any one of the preceding claims, wherein ring A represents:
phenyl optionally substituted with one or more Z2; or
cyclohexyl optionally substituted with one or more Z1.

### Claim 7

The compound according to any one of the preceding claims, wherein each Z1 independently represents —ORd3, —N(Rb3)Rc3, or —N(Rh3)S(O)tRi3.

### Claim 8

The compound according to any one of the preceding claims, each Z2 independently represents —ORd4 or halo.

### Claim 9

The compound according to any one of the preceding claims, wherein up to one Z1 group is present.

### Claim 10

The compound according to any one of the preceding claims, wherein R1 represents H or Me.

### Claim 11

A compound as defined in any one of the preceding claims for use in medicine.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 10, and optionally one or more pharmaceutically acceptable adjuvant, diluent and/or carrier.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A compound as defined in any one of claims 1 to 10, for use in the treatment of hyperglycemia or a disorder characterized by hyperglycemia.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The use of a compound as defined in any one of claims 1 to 10, for the manufacture of a medicament for the treatment of hyperglycemia or a disorder characterized by hyperglycaemia.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treating hyperglycemia or a disorder characterized by hyperglycemia comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in any one of claims 1 to 10.

### Claim 16 (depends on 13, 14, 15)

The compound for use, method or use according to any one of claims 13 to 15, wherein the hyperglycemia or disorder characterised by hyperglycemia is, or is characterised by, the patient displaying severe insulin resistance.

### Claim 17 (depends on 13, 14, 15, 16)

The compound for use, method or use according to any one of claims 13 to 16, wherein the disorder characterised by hyperglycemia is selected from the group consisting of Type 2 diabetes, Rabson-Mendenhall syndrome, Donohue's syndrome (leprechaunism), Type A and Type B syndromes of insulin resistance, the HAIR-AN (hyperandrogenism, insulin resistance, and acanthosis nigricans) syndromes, pseudoacromegaly, and lipodystrophy.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A compound as defined in anyone of claims 1 to 10, for use in the treatment of a non-alcoholic fatty liver disease.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The use of a compound as defined in any one of claims 1 to 10, in the manufacture of a medicament for the treatment or prevention of a non-alcoholic fatty liver disease.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treating or preventing a non-alcoholic fatty liver disease as defined in comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in any one of claims 1 to 10.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A compound as defined in anyone of claims 1 to 10, for use in treating a disease or disorder the treatment of which is mediated by activation of the β2 adrenergic receptor.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The use of a compound as defined in any one of claims 1 to 10, in the manufacture of a medicament for use in treating a disease or disorder the treatment of which is mediated by activation of the β2 adrenergic receptor.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treating a disease or disorder the treatment of which is mediated by activation of the β2 adrenergic receptor comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in any one of claims 1 to 10.
